510(k) Report

510(k) · Cleared

Cleared

Calprest

K130945510(k) TraditionalCleared Jan 16, 2014287-day reviewClass II21 CFR 866.5180

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Eurospital S.P.A. · NXO Calprotectin, Fecal

Cleared on Jan 16, 2014 as substantially equivalent to DEN060001 (Genova Diagnostics, 2006) after a 287-day review. Its family tree reaches back 1 generation to 2006. 10 later devices descend from it.

Decided
Jan 16, 2014
Review
287 days
Class
Class II
Product code
NXO
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to DEN060001 (2006). 10 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2016: 1 descendant cleared2019: 5 descendants cleared2017: 1 descendant cleared2018: 2 descendants cleared2024: 1 descendant clearedDEN060001 · Phical Test · Genova Diagnostics · 200620052010201520202025
Descendants, by generation 1 generation forward: 2 descendants2 generations forward: 4 descendants3 generations forward: 2 descendants4 generations forward: 1 descendant5 generations forward: 1 descendant DEN060001 · Phical Test · Genova Diagnostics · 20060+5
  1. Root · 1 generation backDEN060001 Phical TestGenova Diagnostics · 2006
  2. This deviceK130945 CalprestEurospital S.P.A. · 2014
  3. Descendant · cites it directly · 8 of its ownK160447 Calprest NGEurospital S.P.A. · 2016
  4. Descendant · 2 generations on · 3 of its ownK181012 BUHLMANN fCAL ELISABuhlmann Laboratories AG · 2018
  5. Descendant · 3 generations on · 2 of its ownK190784 BUHLMANN fCAL turboBuhlmann Laboratories AG · 2019
  6. Descendant · 4 generations on · 1 of its ownK191718 Buhlmann fCAL turbo and CALEX CapBuhlmann Laboratories AG · 2019
  7. Descendant · 2 generations on · 1 of its ownK170993 QUANTA Flash Calprotectin Reagents, QUANTA Flash Calprotectin…Inova Diagnostics, Inc. · 2017

Showing 5 of 10 descendants. See all descendants

Descendants cleared per year

2016: 12017: 12018: 22019: 52024: 1
2016high 5 (2019) · low 0 (2020)2026

Most influential descendants

Showing 5 of 10 · See all
  • K160447Calprest NGEurospital S.P.A. · 2016 · cites it directly8descendants
  • K181012BUHLMANN fCAL ELISABuhlmann Laboratories AG · 2018 · 2 generations on3descendants
  • K190784BUHLMANN fCAL turboBuhlmann Laboratories AG · 2019 · 3 generations on2descendants
  • K191718Buhlmann fCAL turbo and CALEX CapBuhlmann Laboratories AG · 2019 · 4 generations on1descendant
  • K170993QUANTA Flash Calprotectin Reagents, QUANTA Flash Calprotectin Calibrators, QUANTA Flash…Inova Diagnostics, Inc. · 2017 · 2 generations on1descendant
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN060001Phical TestGenova Diagnostics2006—
0 (this device)K130945CalprestEurospital S.P.A.2014—
+1K160447Calprest NGEurospital S.P.A.2016—
+2K181012BUHLMANN fCAL ELISABuhlmann Laboratories AG2018—
+3K190784BUHLMANN fCAL turboBuhlmann Laboratories AG2019—
+4K191718Buhlmann fCAL turbo and CALEX CapBuhlmann Laboratories AG2019—
+2K170993QUANTA Flash Calprotectin Reagents, QUANTA Flash Calprotectin Calibrators…Inova Diagnostics, Inc.2017—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201610
201710
201820
201950
202410
FIG. 1 — Lineage of K130945, 2006–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NXO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NXO device

  1. #1 K232057 BÜHLMANN fCAL® turbo and CALEX® Capscore 8.3 · 6 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN060001Phical Test
Our reading of the summary gave K050007, which is not in FDA’s 510(k) list. The device the summary names is FDA’s De Novo DEN060001, Phical Test (Genova Diagnostics), granted Apr 26, 2006; older De Novo requests were first filed under a 510(k) number, so this links to the grant.
Genova Diagnostics2006—

Also cleared against DEN060001: 1 other device →

What descends from it? (10)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K160447Calprest NGEurospital S.P.A.20168
K191589Calprest, EasyCalEurospital S.P.A.20190

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K160447 (Eurospital S.P.A., 2016) has gone furthest, with 8 descendants of its own.
  • 1 other device also cites its predicate DEN060001.

How does its category compare?

All NXO devices

NXO Calprotectin, Fecal: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · NXO

1in 2024

2014: 12016: 12017: 12018: 32019: 52022: 12023: 12024: 1
2007high 5 (2019) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NXO

90in 2019

2018: 90 days median2019: 90 days median
2007high 90 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NXO

2in 2025

2024: 12025: 2
2007high 2 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NXO

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2025

MAUDE reports naming product code NXO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—00
20150—00
20161—00
20171—00
201839000
201959000
20200—00
20210—00
20221—01
20231—00
20241—10
20250—20
20260—0—

What is it indicated for?

Calprest® is a quantitative ELISA for detecting the concentration of fecal calprotectin. Calprest® can be used as an in-vitro diagnostic to aid in the diagnosis of Inflammatory Bowel Diseases (IBD, Crohn's disease and ulcerative colitis) and to differentiate IBD from Irritable Bowel Syndrome (IBS) in conjunction with other clinical and other laboratory findings.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K130945: Calprest.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K130945

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026